IP Library › Granted Patent US 12,655,185
Granted Patent B2
US 12,655,185 · App. 16/319,958 · Granted Jun 16, 2026

Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases

Inventors: Ashok Bhandari (Pleasanton, CA); Xiaoli Cheng (Mountain View, CA); Larry C. Mattheakis (Cupertino, CA)
Assignee: Protagonist Therapeutics, Inc.
C07K14/54A61K9/0019A61K9/0053A61K38/16A61K47/60A61P1/00A61P17/06C07K14/00C07K19/00A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,655,185
App. No.
16/319,958
Granted
Jun 16, 2026
Kind
B2
Abstract

The present invention provides novel peptide inhibitors of interleukin-23, and related methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, Crohn's disease and psoriasis.

Claims (6)

1 . A monomer peptide inhibitor of an interleukin-23 comprising the amino acid sequence set forth in any one of SEQ ID NOs: 3, 8-10, 12, 13, 16, 17, and 19-22, wherein the peptide inhibitor comprises a disulfide bond between the two Cys amino acids of the peptide inhibitor, or a pharmaceutically acceptable salt thereof.

2 . A polynucleotide comprising a sequence encoding the peptide inhibitor of claim 1 .

3 . A vector comprising the polynucleotide of claim 2 .

4 . A pharmaceutical composition comprising the peptide inhibitor or pharmaceutically acceptable salt thereof of claim 1 .

5 . The pharmaceutical composition of claim 4 , further comprising an enteric coating.

6 . The pharmaceutical composition of claim 5 , wherein the enteric coating protects and releases the pharmaceutical composition within a subject's lower gastrointestinal system.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2019
From: BHANDARI, ASHOK; CHENG, XIAOLI; MATTHEAKIS, LARRY C.
To: PROTAGONIST THERAPEUTICS, INC.
Reel/Frame 049888/0898 →
Continuity (2)
Provisional Application 62367549 · Jul 27, 2016
Related Publication 20190270786A1 · Sep 5, 2019
References Cited (400)
US 4684620A · Hruby et al. · 1987 [cited by applicant]
US 4724229A · Ali · 1988 [cited by applicant]
US 5192746A · Lobl et al. · 1993 [cited by applicant]
US 5293050A · Chapple-sokol et al. · 1994 [cited by applicant]
US 5354707A · Chapple-sokol et al. · 1994 [cited by applicant]
US 5494897A · Shikawa et al. · 1996 [cited by applicant]
US 5569741A · Coy et al. · 1996 [cited by applicant]
US 5990084A · Richter et al. · 1999 [cited by applicant]
US 6087334A · Beeley et al. · 2000 [cited by applicant]
US 6235711B1 · Dutta · 2001 [cited by applicant]
US 6818617B1 · Niewiarowski · 2004 [cited by applicant]
US 7534764B2 · Ganz et al. · 2009 [cited by applicant]
US 7589170B1 · Smythe et al. · 2009 [cited by applicant]
US 7718598B1 · Smythe et al. · 2010 [cited by applicant]
US 8313950B2 · Rovin et al. · 2012 [cited by applicant]
US 8435941B2 · Ganz et al. · 2013 [cited by applicant]
US 8536140B2 · Clandinin et al. · 2013 [cited by applicant]
US 8568706B2 · Grabstein et al. · 2013 [cited by applicant]
US 8796418B2 · Walensky et al. · 2014 [cited by applicant]
US 8946150B2 · Gallagher et al. · 2015 [cited by applicant]
US 8999935B2 · Huang · 2015 [cited by applicant]
US 9169292B2 · Gallagher et al. · 2015 [cited by applicant]
US 9273093B2 · Bhandari et al. · 2016 [cited by applicant]
US 9518091B2 · Bhandari et al. · 2016 [cited by applicant]
US 9624268B2 · Bourne et al. · 2017 [cited by applicant]
US 9714270B2 · Bhandari et al. · 2017 [cited by applicant]
US 9809623B2 · Bhandari et al. · 2017 [cited by applicant]
US 9822157B2 · Smythe et al. · 2017 [cited by applicant]
US 10023614B2 · Bhandari et al. · 2018 [cited by applicant]
US 10030061B2 · Smythe et al. · 2018 [cited by applicant]
US 10035824B2 · Bhandari et al. · 2018 [cited by applicant]
US 10059744B2 · Bhandari et al. · 2018 [cited by applicant]
US 10196424B2 · Bourne et al. · 2019 [cited by applicant]
US 10278957B2 · Anandan et al. · 2019 [cited by applicant]
US 10301371B2 · Bhandari et al. · 2019 [cited by applicant]
US 10407468B2 · Bhandari et al. · 2019 [cited by applicant]
US 10442846B2 · Smythe et al. · 2019 [cited by applicant]
US 10501515B2 · Smythe et al. · 2019 [cited by applicant]
US 10626146B2 · Bhandari et al. · 2020 [cited by applicant]
US 10729676B2 · Anandan et al. · 2020 [cited by applicant]
US 10787490B2 · Bhandari et al. · 2020 [cited by applicant]
US 10941183B2 · Bhandari et al. · 2021 [cited by applicant]
US 11041000B2 · Bhandari et al. · 2021 [cited by applicant]
US 11111272B2 · Bhandari et al. · 2021 [cited by applicant]
US 20030166138A1 · Kinsella et al. · 2003 [cited by applicant]
US 20030166514A1 · Jones et al. · 2003 [cited by applicant]
US 20040052785A1 · Goodman et al. · 2004 [cited by applicant]
US 20040123343A1 · La Rosa et al. · 2004 [cited by applicant]
US 20040176293A1 · Peterson et al. · 2004 [cited by applicant]
US 20060008848A1 · Verdine et al. · 2006 [cited by applicant]
US 20060166881A1 · Hotchkiss et al. · 2006 [cited by applicant]
US 20060183884A1 · Blaschuk et al. · 2006 [cited by applicant]
US 20070032417A1 · Baell · 2007 [cited by applicant]
US 20070166308A1 · Pullen et al. · 2007 [cited by applicant]
US 20070191272A1 · Stemmer et al. · 2007 [cited by applicant]
US 20070197430A1 · Baell et al. · 2007 [cited by applicant]
US 20080019913A1 · Polt et al. · 2008 [cited by applicant]
US 20080213277A1 · Sasu et al. · 2008 [cited by applicant]
US 20080260820A1 · Borrelly et al. · 2008 [cited by applicant]
US 20080300180A1 · Schambye et al. · 2008 [cited by applicant]
US 20090053819A1 · Seymour et al. · 2009 [cited by applicant]
US 20090170143A1 · Uttenthal et al. · 2009 [cited by applicant]
US 20090257952A1 · Cochran et al. · 2009 [cited by applicant]
US 20090325810A1 · Lapointe et al. · 2009 [cited by applicant]
US 20100151487A1 · Rovin et al. · 2010 [cited by applicant]
US 20100183617A1 · Herr et al. · 2010 [cited by applicant]
US 20100190710A1 · Chemtob et al. · 2010 [cited by applicant]
US 20100196441A1 · Sondermeijer et al. · 2010 [cited by applicant]
US 20100272731A1 · Presta et al. · 2010 [cited by applicant]
US 20100280098A1 · Juliano et al. · 2010 [cited by applicant]
US 20110059087A1 · Lewis et al. · 2011 [cited by applicant]
US 20110086024A1 · Arthos et al. · 2011 [cited by applicant]
US 20110118186A1 · Schteingart et al. · 2011 [cited by applicant]
US 20110142889A1 · Lee et al. · 2011 [cited by applicant]
US 20110212104A1 · Beaumont et al. · 2011 [cited by applicant]
US 20110282029A1 · Holmes et al. · 2011 [cited by applicant]
US 20120021975A1 · Hoffman et al. · 2012 [cited by applicant]
US 20120040894A1 · Ganz et al. · 2012 [cited by applicant]
US 20120071422A1 · Gallagher et al. · 2012 [cited by applicant]
US 20120115930A1 · Monia et al. · 2012 [cited by applicant]
US 20130029907A1 · Gallagher et al. · 2013 [cited by applicant]
US 20130137123A1 · Cucchiara et al. · 2013 [cited by applicant]
US 20130172272A1 · Gallagher et al. · 2013 [cited by applicant]
US 20130183755A1 · Gallagher et al. · 2013 [cited by applicant]
US 20130310303A1 · Eldar-Finkelman et al. · 2013 [cited by applicant]
US 20130338132A1 · Koshiba et al. · 2013 [cited by applicant]
US 20140005128A1 · Mo et al. · 2014 [cited by applicant]
US 20140193465A1 · Bhandari et al. · 2014 [cited by applicant]
US 20140286953A1 · Sasu et al. · 2014 [cited by applicant]
US 20140294901A1 · Bhandari et al. · 2014 [cited by applicant]
US 20140294902A1 · Bhandari et al. · 2014 [cited by applicant]
US 20140336110A1 · Ganz et al. · 2014 [cited by applicant]
US 20150056301A1 · Kawabe et al. · 2015 [cited by applicant]
US 20150118315A1 · Wilson · 2015 [cited by applicant]
US 20150157692A1 · Fu · 2015 [cited by applicant]
US 20150203555A1 · Gellman · 2015 [cited by examiner]
US 20150284429A1 · Merutka · 2015 [cited by applicant]
US 20160031944A1 · Bhandari et al. · 2016 [cited by applicant]
US 20160039878A1 · Gallagher et al. · 2016 [cited by applicant]
US 20160145306A1 · Bourne et al. · 2016 [cited by applicant]
US 20160152664A1 · Bhandari et al. · 2016 [cited by applicant]
US 20160159862A1 · Bhandari et al. · 2016 [cited by applicant]
US 20160199437A1 · Wilson · 2016 [cited by applicant]
US 20160222076A1 · Smythe et al. · 2016 [cited by applicant]
US 20160228491A1 · Wilson · 2016 [cited by applicant]
US 20160368966A1 · Bhandari et al. · 2016 [cited by applicant]
US 20170313754A1 · Bourne et al. · 2017 [cited by applicant]
US 20170327541A1 · Bhandari et al. · 2017 [cited by applicant]
US 20180022778A1 · Bourne et al. · 2018 [cited by applicant]
US 20180079782A1 · Bhandari et al. · 2018 [cited by applicant]
US 20180079783A1 · Bhandari et al. · 2018 [cited by applicant]
US 20180099995A1 · Bhandari et al. · 2018 [cited by applicant]
US 20180100004A1 · Smythe et al. · 2018 [cited by applicant]
US 20180105572A1 · Bhandari et al. · 2018 [cited by applicant]
US 20180148477A1 · Bhandari et al. · 2018 [cited by applicant]
US 20190002500A1 · Bhandari et al. · 2019 [cited by applicant]
US 20190002503A1 · Bourne et al. · 2019 [cited by applicant]
US 20190016756A1 · Bhandari et al. · 2019 [cited by applicant]
US 20190076400A1 · Anandan et al. · 2019 [cited by applicant]
US 20190185535A1 · Smythe et al. · 2019 [cited by applicant]
US 20190185536A1 · Smythe et al. · 2019 [cited by applicant]
US 20190231746A1 · Anandan et al. · 2019 [cited by applicant]
US 20190248870A1 · Bhandari et al. · 2019 [cited by applicant]
US 20190264197A1 · Barkan et al. · 2019 [cited by applicant]
US 20190300590A1 · Bhandari et al. · 2019 [cited by applicant]
US 20190337983A1 · Bhandari et al. · 2019 [cited by applicant]
US 20200017549A1 · Bhandari et al. · 2020 [cited by applicant]
US 20200017566A1 · Bourne et al. · 2020 [cited by applicant]
US 20200040037A1 · Bhandari et al. · 2020 [cited by applicant]
US 20200064357A1 · Cheng et al. · 2020 [cited by applicant]
US 20200207822A1 · Bhandari et al. · 2020 [cited by applicant]
US 20200239516A1 · Richelle et al. · 2020 [cited by applicant]
US 20200239523A1 · Bhandari et al. · 2020 [cited by applicant]
US 20200361992A1 · Bourne et al. · 2020 [cited by applicant]
US 20210061872A1 · Liu et al. · 2021 [cited by applicant]
US 20210147483A1 · Bourne et al. · 2021 [cited by applicant]
US 20210261622A1 · Sun et al. · 2021 [cited by applicant]
US 20210363185A1 · Bhandari et al. · 2021 [cited by applicant]
US 20210371466A1 · Bhandari et al. · 2021 [cited by applicant]
US 20220041658A1 · Bhandari et al. · 2022 [cited by applicant]
CA 2015761A1 · 1990 [cited by applicant]
CL 2018000128A1 · 2018 [cited by applicant]
CL 2018003322A1 · 2019 [cited by applicant]
CN 101307085A · 2008 [cited by applicant]
CN 101358201A · 2009 [cited by applicant]
DE 10107707A1 · 2002 [cited by applicant]
EP 0396526A2 · 1990 [cited by applicant]
JP 2010517529A · 2010 [cited by applicant]
JP 2010536364A · 2010 [cited by applicant]
JP 2011231085A · 2011 [cited by applicant]
JP 2012525124A · 2012 [cited by applicant]
JP 2016521257A · 2016 [cited by applicant]
JP 2017530090A · 2017 [cited by applicant]
WO WO1992017492A1 · 1992 [cited by applicant]
WO WO9411018A1 · 1994 [cited by applicant]
WO WO9617617A1 · 1996 [cited by applicant]
WO WO1997007129A1 · 1997 [cited by applicant]
WO WO1997025351A2 · 1997 [cited by applicant]
WO WO1998008871A1 · 1998 [cited by applicant]
WO WO2000055184A1 · 1998 [cited by applicant]
WO WO9833524A1 · 1998 [cited by applicant]
WO WO1999002194A1 · 1999 [cited by applicant]
WO WO1999026615A1 · 1999 [cited by applicant]
WO WO2000006243A2 · 2000 [cited by applicant]
WO WO2000009560A1 · 2000 [cited by applicant]
WO WO2000018789A1 · 2000 [cited by applicant]
WO WO2000018790A1 · 2000 [cited by applicant]
WO WO2000023474A1 · 2000 [cited by applicant]
WO WO2000055119A1 · 2000 [cited by applicant]
WO WO2000061580A1 · 2000 [cited by applicant]
WO WO2001068586A2 · 2001 [cited by applicant]
WO WO2003066678A1 · 2003 [cited by applicant]
WO WO2004011650A2 · 2004 [cited by applicant]
WO WO2004092405A2 · 2004 [cited by applicant]
WO WO2006032104A1 · 2006 [cited by applicant]
WO WO2007076524A2 · 2007 [cited by applicant]
WO WO2007138291A2 · 2007 [cited by applicant]
WO WO2008097461A2 · 2008 [cited by applicant]
WO WO2008101017A2 · 2008 [cited by applicant]
WO WO2008134659A2 · 2008 [cited by applicant]
WO WO2008140602A2 · 2008 [cited by applicant]
WO WO2009002947A2 · 2008 [cited by applicant]
WO WO2009027752A2 · 2009 [cited by applicant]
WO WO2010017598A1 · 2010 [cited by applicant]
WO WO2010065815A2 · 2010 [cited by applicant]
WO WO2010116752A1 · 2010 [cited by applicant]
WO WO2010124874A1 · 2010 [cited by applicant]
WO WO2011091357A1 · 2011 [cited by applicant]
WO WO2011149942A2 · 2011 [cited by applicant]
WO WO2012052205A1 · 2012 [cited by applicant]
WO WO2013086143A1 · 2013 [cited by applicant]
WO WO2014059213A1 · 2014 [cited by applicant]
WO WO2014127316A2 · 2014 [cited by applicant]
WO WO2014145561A2 · 2014 [cited by applicant]
WO WO2014165448A1 · 2014 [cited by applicant]
WO WO2014165449A1 · 2014 [cited by applicant]
WO WO2014210056A1 · 2014 [cited by applicant]
WO WO2015054500A2 · 2015 [cited by applicant]
WO WO2015157283A9 · 2015 [cited by applicant]
WO WO2015176035A1 · 2015 [cited by applicant]
WO WO2015183963A2 · 2015 [cited by applicant]
WO WO2015200916A2 · 2015 [cited by applicant]
WO WO2016004093A2 · 2016 [cited by applicant]
WO WO2016011208A1 · 2016 [cited by applicant]
WO WO2016054411A1 · 2016 [cited by applicant]
WO WO2016054445A1 · 2016 [cited by applicant]
WO WO2016109363A1 · 2016 [cited by applicant]
WO WO2016115168A1 · 2016 [cited by applicant]
WO WO2016195663A1 · 2016 [cited by applicant]
WO WO2016200364A1 · 2016 [cited by applicant]
WO WO2017011820A2 · 2017 [cited by applicant]
WO WO2017117411A1 · 2017 [cited by applicant]
WO WO2017165676A1 · 2017 [cited by applicant]
WO WO2018022937A1 · 2018 [cited by applicant]
WO WO2018022917A1 · 2018 [cited by applicant]
WO WO2018089693A2 · 2018 [cited by applicant]
WO WO2018136646A1 · 2018 [cited by applicant]
WO WO2019051494A1 · 2019 [cited by applicant]
WO WO2019157268A1 · 2019 [cited by applicant]
WO WO2019246273A1 · 2019 [cited by applicant]
WO WO2019246349A1 · 2019 [cited by applicant]
WO WO2020014646A1 · 2020 [cited by applicant]
WO WO2020198682A1 · 2020 [cited by applicant]
WO WO2021007433A1 · 2021 [cited by applicant]
WO WO2021046246A1 · 2021 [cited by applicant]
WO WO2021142373A1 · 2021 [cited by applicant]
WO WO2021146441A1 · 2021 [cited by applicant]
WO WO2021146454A1 · 2021 [cited by applicant]
WO WO2021146458A1 · 2021 [cited by applicant]
WO WO2022026629A1 · 2022 [cited by applicant]
WO WO2022026631A1 · 2022 [cited by applicant]
WO WO2022026633A1 · 2022 [cited by applicant]
WO WO2022109328A1 · 2022 [cited by applicant]
WO WO2022212696A1 · 2022 [cited by applicant]
WO WO2022212698A1 · 2022 [cited by applicant]
WO WO2022212700A2 · 2022 [cited by applicant]
WO WO2022266060A1 · 2022 [cited by applicant]
WO WO2023288017A2 · 2023 [cited by applicant]
WO WO2023288019A2 · 2023 [cited by applicant]
WO WO2023288028A2 · 2023 [cited by applicant]
WO WO2023009891A2 · 2023 [cited by applicant]
WO WO2023150618A2 · 2023 [cited by applicant]
WO WO2023150630A2 · 2023 [cited by applicant]
WO WO2023240077A1 · 2023 [cited by applicant]
WO WO2024011188A1 · 2024 [cited by applicant]
WO WO2024110477A2 · 2024 [cited by applicant]
WO WO2025207760A1 · 2025 [cited by applicant]
Araghi et al. Designing helical peptide inhibitors of protein-protein Interactions. Current Opinion in Structural Biology 2016, 39:27-38. [cited by examiner]
Webster et al. Engineered Two-Helix Small Proteins for Molecular Recognition. ChemBioChem 2009, 10, 1293-1296. [cited by examiner]
Chang, et al., Role of disulfide bonds in the structure and activity of human insulin. Mol Cells (Dec. 2003); 16(3): 323-330. [cited by applicant]
Clark, et al., “The Engineering of an Orally Active Conotoxin for the Treatment of Neuropathic Pain.” Angew Chem Int Ed (Sep. 2010); 49: 6545-6548. [cited by applicant]
Craik, et al., “Potential therapeutic applications of the cyclotides and related cystine knot mini-proteins.” Expert Opin Investig Drugs (May 2007); 16(5): 595-604. [cited by applicant]
De Vega, et al., “Modulation of Protein-Protein Interactions by Stabilizing/Mimicking Protein Secondary Structure Elements.” Curr Top Med Chem (2007); 7(1): 33-62. [cited by applicant]
Dutton, et al., “A New Level of Conotoxin Diversity, a Non-native Disulfide Bond Connectivity in—Conotoxin AulB Reduces Structural Definition but Increases Biological Activity.” J Biol Chem (Oct. 2002); 277(50): 48849-4… [cited by applicant]
Fass, D., “Disulfide bonding in protein biophysics.” Annu Rev Biophys (2012); 41: 63-79. Epub Dec. 20, 2011. [cited by applicant]
Fosgerau and Hoffman, “Peptide therapeutics: current status and future directions.” Drug Discovery Today (2015); 20(1): 122-128. [cited by applicant]
Foster “Deuterium Isotope Effects in Studies of Drug Metabolism”, Trends Pharmacol. Sci. (1984); 5(12): 524-527. [cited by applicant]
Francis, G., et al., “PEGylation of Cytokines and other Therapeutic Proteins and Peptides: the Importance of Biological Optimisation of Coupling Techniques,” International Journal of Hematology, Jul. 1998, vol. 68, pp. … [cited by applicant]
Garcia, Josep et al., “D-Polyarginine Lipopeptides as Intestinal Permeation Enhancers”. ChemMedChem Oct. 8, 2018; 13(19): 2045-2052. Epub Aug. 20, 2018. [cited by applicant]
Gombotz and Pettit, “Biodegradable Polymers for Protein and Peptide Drug Delivery”. Bioconjugate Chem. (Jul. 1, 1995); 6(4): 332-351. [cited by applicant]
Gruschow, et al., “New pacidamycin antibiotics through precursor-directed biosynthesis”. Chembiochem. Jan. 26, 2009; 10(2): 355-360. [cited by applicant]
Guerler and Knapp, “Novel protein folds and their nonsequential structural analogs.” Protein Sci (Aug. 2008); 17(8): 1374-1382. [cited by applicant]
Guharoy and Chakrabarti, “Secondary structure based analysis and classification of biological interfaces: identification of binding motifs in protein-protein interactions.” Bioinformatics (2007); 23(15): 1909-1918. Epub… [cited by applicant]
Gupta, et al., “A classification of disulfide patterns and its relationship to protein structure and function.” Protein Sci (Aug. 2004); 13(8): 2045-2058. [cited by applicant]
Hartig, et al., “Intramolecular disulphide bond arrangements in nonhomologous proteins.” Protein Sci Publ Protein Soc (Feb. 2005); 14(2): 474-482. [cited by applicant]
Henikoff and Henikoff, “Amino acid substitution matrices from protein blocks.” Proc Natl Acad Sci U S A (Nov. 1992); 89(Nov.); 10915-10919. [cited by applicant]
Liu, Shuang, “Radiolabeled Multimeric Cyclic Rgd Peptides as Integrin Alphavbeta3 Targeted Radiotracers For Tumor Imaging” School of Health Science, Purdue University, Molecular Pharmaceuticals (2006); 3(5):472-487. [cited by applicant]
Maher, Sam et al., “Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic”. Advanced Drug Delivery Reviews Dec. 17, 2009; 61 (15): 1427-1449. Epub Oct. 1, 2009. [cited by applicant]
Maher, Sam et al., “Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update”. Pharmaceutics Jan. 19, 2019; 11(1): 41, 23 pages. [cited by applicant]
Muheem, Abdul et al., “A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives”. Saudi Pharmaceutical Journal Jul. 2016; 24(4):413-428. Epub Jun. 16, 2014. [cited by applicant]
Rubinstein and Niv, “Peptidic modulators of protein-protein interactions: Progress and challenges in computational design.” Biopolymers (2009); 91(7): 505-513. [cited by applicant]
Tsukada, et al., “An Anti-α-Fetoprotein Antibody-Daunorubicin Conjugate With a Novel Poly-L-glutamic Acid Derivative as Intermediate Drug Carrier ”. J. Natl. Cancer Inst. (Sep. 1984); 73(3): 721-729. [cited by applicant]
White and Yudin, “Contemporary strategies for peptide macrocyclization.” Nat Chem (Jun. 2011); 3(7): 509-524. [cited by applicant]
U.S. Appl. No. 14/714,198, filed May 15, 2015, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 14/775,469, filed Mar. 17, 2014, Smythe, et al. [cited by applicant]
U.S. Appl. No. 14/800,627, filed Jul. 15, 2015, Bourne, et al. [cited by applicant]
U.S. Appl. No. 14/872,975, filed Oct. 1, 2015, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 15/000,923, filed Jan. 19, 2016, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 15/046,325, filed Feb. 17, 2016, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 15/255,750, filed Sep. 2, 2016, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 15/258,540, filed Sep. 7, 2016, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 15/321,124, filed Dec. 21, 2016, Bourne, et al. [cited by applicant]
U.S. Appl. No. 15/442,229, filed Feb. 24, 2017, Bourne, et al. [cited by applicant]
U.S. Appl. No. 15/467,810, filed Mar. 23, 2017, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 15/514,983, filed Mar. 28, 2017, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 15/614,047, filed Jun. 5, 2017, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 15/698,407, filed Sep. 7, 2017, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 15/720,333, filed Sep. 29, 2017, Smythe, et al. [cited by applicant]
U.S. Appl. No. 15/828,214, filed Nov. 30, 2017, Smythe, et al. [cited by applicant]
U.S. Appl. No. 15/831,087, filed Dec. 4, 2017, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 15/831,099, filed Dec. 4, 2017, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 15/831,100, filed Dec. 4, 2017, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 15/831,120, filed Dec. 4, 2017, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 15/836,648, filed Dec. 8, 2017, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/035,060, filed Jul. 13, 2018, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/037,982, filed Jul. 17, 2018, Smythe, et al. [cited by applicant]
U.S. Appl. No. 16/039,813, filed Jul. 19, 2018, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/113,072, filed Aug. 27, 2018, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/128,352, filed Sep. 11, 2018, Anandan, et al. [cited by applicant]
U.S. Appl. No. 16/217,864, filed Dec. 12, 2018, Bourne, et al. [cited by applicant]
U.S. Appl. No. 16/282,908, filed Feb. 22, 2019, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/417,075, filed May 20, 2019, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/510,118, filed Jul. 12, 2019, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/774,686, filed Jan. 28, 2020, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/780,297, filed Feb. 3, 2020, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/781,516 filed Filed Feb. 4, 2020, Bhandari, et al.. [cited by applicant]
U.S. Appl. No. 16/839,368, filed Apr. 3, 2020, Smythe, et al. [cited by applicant]
U.S. Appl. No. 16/856,521, filed Apr. 23, 2020, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/931,046, filed Jul. 16, 2020, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/940,989, filed Jul. 28, 2020, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/964,708, filed Jul. 24, 2020, Bourne, et al. [cited by applicant]
U.S. Appl. No. 17/001,428, filed Aug. 24, 2020, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 17/011,844, filed Sep. 3, 2020, Liu, et al. [cited by applicant]
U.S. Appl. No. 17/061,336, filed Oct. 1, 2020, Bourne, et al. [cited by applicant]
U.S. Appl. No. 17/084,225, filed Oct. 29, 2020, Bourne, et al. [cited by applicant]
U.S. Appl. No. 17/099,308, filed Nov. 16, 2020, Smythe, et al. [cited by applicant]
U.S. Appl. No. 17/104,596, filed Nov. 25, 2020, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 17/137,049, filed Dec. 29, 2020, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 17/149,509, filed Jan. 14, 2021, Sun, et al. [cited by applicant]
U.S. Appl. No. 17/149,544, filed Jan. 14, 2021, Sun, et al. [cited by applicant]
U.S. Appl. No. 17/161,370, filed Jan. 28, 2021, Bhandari, et al. [cited by applicant]
Brayden, D.J., and Mrsny, R.J., “Oral peptide delivery: prioritizing the leading technologies”. Therapeutic Delivery (2011); 2(12): 1567-1573. [cited by applicant]
Cherry, et al., “Vedolizumab: an a437 integrin antagonist for ulcerative colitis and Crohn's disease.” Ther Adv Chronic Dis. (2015); 6(5): 224-233. [cited by applicant]
European Application No. 18741939.5, Partial Supplementary European Search Report dated Aug. 26, 2020, 13 pages. [cited by applicant]
European Application No. 18741939.5, Extended European Search Report dated Nov. 27, 2020, 11 pages. [cited by applicant]
European Application No. 17771175.1, Partial Supplementary European Search Report dated Nov. 25, 2019, 15 pages. [cited by applicant]
European Application No. 17771175.1, Extended European Search Report dated Mar. 4, 2020, 11 pages. [cited by applicant]
Gentilucci, et al., “Chemical Modifications Designed to Improve Peptide Stability: Incorporation of Non-Natural Amino Acids, Pseudo-Peptide Bonds, and Cyclization”. Curr Pharm Des. (2010); 16(28): 3185-3203. [cited by applicant]
Görmer, et al., “Efficient Microwave-Assisted Synthesis of Unsymmetrical Disulfides”, J. Org. Chem. (Feb. 1, 2010); 75(5): 1811-1813. [cited by applicant]
Kuchař, et al., “Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells”. Proteins (Jun. 2014); 82(6): 975-989. Epu… [cited by applicant]
Makharia, Govind K., “Current and emerging therapy for celiac disease”, Frontiers in Medicine (Mar. 2014); vol. 1, Article 6, pp. 1-11. [cited by applicant]
PCT/US2017/023859, Invitation to Pay Additional Fees, mailed May 25, 2017, 9 pages. [cited by applicant]
PCT/US2017/023859, International Preliminary Report on Patentability, dated Sep. 25, 2018, 9 pages. [cited by applicant]
PCT/US2017/023859, International Search Report and Written Opinion, mailed Jul. 26, 2017, 14 pages. [cited by applicant]
PCT/US2017/060944, International Preliminary Report on Patentability dated May 21, 2019, 8 pages. [cited by applicant]
PCT/US2017/060944, International Search Report and Written Opinion mailed Feb. 2, 2020, 10 pages. [cited by applicant]
PCT/US2018/050480, International Preliminary Report on Patentability dated Mar. 17, 2020, 7 pages. [cited by applicant]
PCT/US2019/017192, International Search Report and Written Opinion, mailed Jun. 11, 2019, 13 pages. [cited by applicant]
PCT/US2019/041665, International Preliminary Report on Patentability, mailed Jan. 12, 2021, 7 pages. [cited by applicant]
PCT/US2020/041409, International Search Report and Written Opinion, mailed Dec. 3, 2020, 17 pages. [cited by applicant]
PCT/US2020/041409, Invitation to pay additional search fees, mailed Sep. 28, 2020, 2 pages. [cited by applicant]
Quiniou, et al., “Specific targeting of the IL-23 receptor, using a novel small peptide noncompetitive antagonist, decreases the inflammatory response”. Am J Physiol Regul Integr Comp Physiol. (Nov. 15, 2014); 307(10): … [cited by applicant]
U.S. Appl. No. 15/467,810, Notice of Allowability dated Mar. 13, 2019, 8 pages. [cited by applicant]
U.S. Appl. No. 16/067,568, Office Action mailed Apr. 2, 2020, 15 pages. [cited by applicant]
U.S. Appl. No. 16/478,733, Office Action mailed Sep. 9, 2020, 24 pages. [cited by applicant]
U.S. Appl. No. 16/510,118, Office Action mailed Sep. 4, 2020, 16 pages. [cited by applicant]
U.S. Appl. No. 17/001,428, Notice of Allowance mailed Feb. 10, 2021, 9 pages. [cited by applicant]
Chermahini et al., “Cyclic peptide nanocapsule as ion carrier for halides: a theoretical survey.” Structural Chemistry (Oct. 2018); 29(5): 1351-1357. [cited by applicant]
Dyson, G., et al., “May's Chemistry of Synthetic Drugs.” Fifth Edition, Longmans, London (1959); pp. 12-19. [cited by applicant]
Kong et al., “De novo development of proteolytically resistant therapeutic peptides for oral administration.” Nat Biomed Eng. May 2020; 4(5): 560-571. doi: 10.1038/s41551-020-0556-3. Epub May 11, 2020. [cited by applicant]
Qi, Y., et al., “A Diaminodiacid (DADA) Strategy for the Development of Disulfide Surrogate Peptides.” Chem Asian J. Sep. 15, 2020; 15(18): 2793-2802. doi: 10.1002/asia.202000609. Epub Aug. 11, 2020. [cited by applicant]
Sawyer, T.K., et al., “Macrocyclic a helical peptide therapeutic modality: A perspective of learnings and challenges.” Bioorg Med Chem. Jun. 1, 2018; 26(10): 2807-2815. doi: 10.1016/j.bmc.2018.03.008. Epub Mar. 16, 2018. [cited by applicant]
Annis, et al., “[10] Disulfide bond formation in peptides”. Methods Enzymol. (1997); 289: 198-221. [cited by applicant]
Cheng et al., “The Biomarker Profile of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor, Tracks with Efficacy in a Preclinical Model of IBD”. Gastroenterology, AGA Abstracts, vol. 152, Issue 5, Supplement 1, S31, … [cited by applicant]
Delgado et al., “The uses and properties of PEG-linked proteins”. Critical Reviews in Therapeutic Drug Carrier Systems (Jan. 1, 1992); 9(3-4): 249-304. [cited by applicant]
Hruby, et al., “Recent Developments in the Design of Receptor Specific Opioid Peptides.” Medicinal Research Reviews (1989); 9(3): 343-401. [cited by applicant]
Hu, et al., “Synthesis and biological evaluations of novel endomorphin analogues containing α-hydroxy-β-phenylalanine (AHPBA) displaying mixed μ/δopioid receptor agonist and δ opioid receptor antagonist activities”. Eur… [cited by applicant]
Hudecz, et al., “Synthesis, conformation, biodistribution and in vitro cytotoxicity of daunomycin-branched polypeptide conjugates”. Bioconjugate Chem. (Jan. 1, 1992); 3(1): 49-57. [cited by applicant]
Liu and Wang, “Endomorphins: potential roles and therapeutic indications in the development of opioid peptide analgesic drugs”. Med Res Rev. (May 2012); 32(3): 536-580. Epub Feb. 1, 2011. [cited by applicant]
Longobardo, et al., “β-Casomorphins: substitution of phenylalanine with β-homo-phenylalanine increases the μ-type opioid receptor affinity.” Bioorganic & Medicinal Chemistry Letters (2000); 10(11): 1185-1188. [cited by applicant]
Longobardo, et al., “Incorporation of ß-amino acids in bioactive peptides: a β- casomorphin case study.” Peptides 2002, Abstract P A97, Proceedings of the European Peptide Symposium, 27th, Sorrento, Italy, Aug. 31-Sep. … [cited by applicant]
Maeda, et al., “Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo”. Bioconjugate Chem. (Sep./Oct. 1992); 3(5): 351-362. [cited by applicant]
U.S. Appl. No. 17/149,544 entitled “Peptide inhibitors of INTERLEUKIN-23 receptor and their use to treat inflammatory diseases” filed Jan. 14, 2021, 174 pages. [cited by applicant]
Witt, Dariusz, “Recent developments in disulfide bond formation”. Synthesis (2008); 16: 2491-2509. [cited by applicant]
Zalipsky, Samuel, “Functionalized Poly(ethylene glycols) for Preparation of Biologically Relevant Conjugates”. Bioconjugate Chem. (1995); 6(2): 150-165. [cited by applicant]
U.S. Appl. No. 15/486,684, filed Apr. 13, 2017, Bhandari et al. [cited by applicant]
U.S. Appl. No. 15/493,471, filed Apr. 21, 2017, Bhandari et al. [cited by applicant]
U.S. Appl. No. 15/745,371, filed Jan. 16, 2018, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/282,920, filed Feb. 22, 2019, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/348,293, filed May 8, 2019, Cheng, et al. [cited by applicant]
U.S. Appl. No. 16/376,565, filed Apr. 5, 2019, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/382,783, filed Apr. 12, 2019, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/439,435, filed Jun. 12, 2019, Bourne, et al. [cited by applicant]
U.S. Appl. No. 16/478,733, filed Jul. 29, 2019, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/553,486, filed Aug. 28, 2019, Smythe, et al. [cited by applicant]
U.S. Appl. No. 16/656,339, filed Oct. 17, 2019, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/689,884, filed Nov. 20, 2019, Bhandari, et al. [cited by applicant]
U.S. Appl. No. 16/700,659, filed Dec. 2, 2019, Bhandari, et al. [cited by applicant]
Adams and Macmillan, “Investigation of peptide thioester formation via N→Se acyl transfer.” Journal of Peptide Science (2013); 19 (2): 65-73. [cited by applicant]
Andreu, et al., “Formation of Disulfide Bonds in Synthetic Peptides and Proteins” in Synthetic Peptides and Proteins. In: Pennington M.W., Dunn B.M. (eds) Peptide Synthesis Protocols. Methods in Molecular Biology (1994)… [cited by applicant]
Ashby, et al., “Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease.” Kidney International (2009); 75 (9): 976-981. [cited by applicant]
Balasubramanian and Kuppuswamy, “RGD-containing Peptides Activate S6K1 through β [cited by applicant]
Boer, J., et al., “Design and Synthesis of Potent and Selective α [cited by applicant]
Bowie, et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions.” Science (1990); 247: 1306-1310. [cited by applicant]
Chatterjee, J. et al., “N-Methylation of Peptides: a New Perspective in Medicinal Chemistry”, Accounts of Chemical Research, 41(10): 1331-1342 (2008). [cited by applicant]
Clark, et al., “Understanding the Structure/Activity Relationships of the Iron Regulatory Peptide Hepcidin.” Chem Biol. (Mar. 2011); 18(3): 336-343. [cited by applicant]
Clark, Richard J., et al. “Design, synthesis, and characterization of cyclic analogues of the iron regulatory peptide hormone hepcidin.” Peptide Science (2013); 100.5: 519-526. [cited by applicant]
Database EPO Proteins [Online] Dec. 3, 2010 (Dec. 3, 2010), “Sequence from Patent WO2010124874.” XP002761649, retrieved from EBI accession No. EPOP:HI656765 Database accession No. HI656765, 1 page. [cited by applicant]
Database USPTO Proteins [Online] Dec. 17, 2012 (Dec. 17, 2012), “Sequence from patent U.S. Pat. No. 8,313,950.”, XP002761650, retrieved from EBI accession No. USPOP:AGA36544 Database accession No. AGA36544, 1 page. [cited by applicant]
Davies, J.S., “The Cyclization of Peptides and Depsipeptides”, J Pept Sci. (Aug. 2003); 9(8): 471-501. [cited by applicant]
De Mast, et al., “Increased serum hepcidin and alterations in blood iron parameters associated with asymptomatic P. falciparum and P. vivax malaria.” Haematologica (2010); 95 (7): 1068-1074. [cited by applicant]
Definition of Isostere, Medical Definition and More from Merriam-Webster Dictionary, 3 pages, www.merriam-webster.com/medical/isostere accessed on Feb. 5, 2015. [cited by applicant]
Desbenoit, N., et al. “Reversible metalation of a bis-disulfide analogue of the Cys*-X-Cys* hepcidin binding site: structural characterisation of the related copper complex].” Annales Pharmaceutiques Francaises (2010); … [cited by applicant]
Dolain, Christel, et al. “Inducing α-Helices in Short Oligopeptides through Binding by an Artificial Hydrophobic Cavity.” Journal of the American Chemical Society (2010); 132.16: 5564-5565. [cited by applicant]
Dubree, Nathan J.P. et al., “Selective a4B7 Integrin Antagonists and Their Potential as Antiinflammatory Agents”, J. Med. Chem., 45: 3451-3457 (2002). [cited by applicant]
Dutta, Anand S., “Potent Cyclic Monomeric and Dimeric Peptide Inhibitors of VLA-4 (a4b1 Integrin)-Mediated Cell Adhesion Based on the lle-Leu-Asp-Val Tetrapeptide”, J. Peptide Sci. (2000); 6: 321-341. [cited by applicant]
European Application No. 13845982.1, Extended European Search Report dated May 13, 2016. [cited by applicant]
European Application No. 14763104.8, Extended European Search Report dated Sep. 23, 2016, 10 pages. [cited by applicant]
European Application No. 14779463.0, Extended European Search Report mailed Nov. 9, 2016, 9 pages. [cited by applicant]
European Application No. 14780207.8, Extended European Search Report mailed Feb. 17, 2017, 9 pages. [cited by applicant]